Brooke L. Billman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brooke L. Billman has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Alex J. Rai
2 shared publications- Alexander Joseph Lazar
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
2 shared publications - Apostolia Maria Tsimberidou
The University of Texas MD Anderson Cancer Center, Houston, TX
2 shared publications Carolyn Compton
2 shared publications- Christina M. Lockwood
Department of Laboratory Medicine and Pathology, University of Washington School of Medicine , Seattle, WA
2 shared publications Daniel F. Hayes
2 shared publications
Latest Publications
- Open Access
- 25 February 2021
- Published by IU Indianapolis University Library in Hypothesis
- Vol. 31 (1)
Benchmarking study of hospital libraries
Objectives: To assess the current landscape of hospital libraries by collecting benchmarking data from hospital librarians in the U.S. and other countries. Since the last MLA benchmarking survey in 2002 hospital libraries have faced significant changes including downsizing, position and library elimination, and hospital mergers. This survey will provides information to inform the development and implementation of effective advocacy for hospital libraries. Methods: A web-based, anonymous survey was designed to collect information from hospital librarians representing stand-alone hospitals and hospital systems. The 57-question survey was distributed via select list servs, targeting the US and Canada but open to any country. The topic areas covered hospital/health system, library, and library staff demographics; library characteristics and scope of service; interlibrary loan and document delivery; library funding; and library budget. Hospital library benchmarking surveys, including the previous MLA surveys, were reviewed and applicable questions were added. Results: There were a total of 180 respondents but the total number of responses for each question varied. Select results are as follows: of the responding libraries, 67.2% were part of a hospital system; 24.4% had merged with or were bought by another hospital or health system and, of those, 77.1% had acquired 1-5 hospitals in the last 10 years; 77.9% were not for profits; over half (55.2%) had <5,001 FTE in the organization; 56.9% had one library; 47.7% had 1 FTE librarian, 34.9% had 2-5; 82.1% did not or were not able to use social media; 60.7% didn’t have strategic plans; 66.1% belonged to a consortium; 48.2% provided up to 250 search requests a year; 66.3% did not receive funding outside of their organization; 32.5% had budgets for print books totaling less than $1,000; 30.1% had budgets, excluding salaries, of less than $100,000 and 9.7% had budgets over $1M. Conclusions: These findings contribute to the field’s knowledge of hospital library demographics as well as the services provided. The results suggest implications for hospital librarians regarding staffing levels and the depth of services within their unique settings, especially within the context of rapidly expanding health systems.
- 25 February 2021
- Published by IU Indianapolis University Library in Hypothesis
- Vol. 31 (1)
Open AccessBenchmarking study of hospital libraries
Objectives: To assess the current landscape of hospital libraries by collecting benchmarking data from hospital librarians in the U.S. and other countries. Since the last MLA benchmarking survey in 2002 hospital libraries have faced significant changes including downsizing, position and library elimination, and hospital mergers. This survey will provides information to inform the development and implementation of effective advocacy for hospital libraries. Methods: A web-based, anonymous survey was designed to collect information from hospital librarians representing stand-alone hospitals and hospital systems. The 57-question survey was distributed via select list servs, targeting the US and Canada but open to any country. The topic areas covered hospital/health system, library, and library staff demographics; library characteristics and scope of service; interlibrary loan and document delivery; library funding; and library budget. Hospital library benchmarking surveys, including the previous MLA surveys, were reviewed and applicable questions were added. Results: There were a total of 180 respondents but the total number of responses for each question varied. Select results are as follows: of the responding libraries, 67.2% were part of a hospital system; 24.4% had merged with or were bought by another hospital or health system and, of those, 77.1% had acquired 1-5 hospitals in the last 10 years; 77.9% were not for profits; over half (55.2%) had <5,001 FTE in the organization; 56.9% had one library; 47.7% had 1 FTE librarian, 34.9% had 2-5; 82.1% did not or were not able to use social media; 60.7% didn’t have strategic plans; 66.1% belonged to a consortium; 48.2% provided up to 250 search requests a year; 66.3% did not receive funding outside of their organization; 32.5% had budgets for print books totaling less than $1,000; 30.1% had budgets, excluding salaries, of less than $100,000 and 9.7% had budgets over $1M. Conclusions: These findings contribute to the field’s knowledge of hospital library demographics as well as the services provided. The results suggest implications for hospital librarians regarding staffing levels and the depth of services within their unique settings, especially within the context of rapidly expanding health systems.
- 1 August 2020
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 144 (8) , 933-958
Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology
Context.—: The need for appropriate specimen use for ancillary testing has become more commonplace in the practice of pathology. This, coupled with improvements in technology, often provides less invasive methods of testing, but presents new challenges to appropriate specimen collection and handling of these small specimens, including thoracic small biopsy and cytology samples. Objective.—: To develop a clinical practice guideline including recommendations on how to obtain, handle, and process thoracic small biopsy and cytology tissue specimens for diagnostic testing and ancillary studies. Methods.—: The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. Core needle biopsy, touch preparation, fine-needle aspiration, and effusion specimens with thoracic diseases including malignancy, granulomatous process/sarcoidosis, and infection (eg, tuberculosis) were deemed within scope. Ancillary studies included immunohistochemistry and immunocytochemistry, fluorescence in situ hybridization, mutational analysis, flow cytometry, cytogenetics, and microbiologic studies routinely performed in the clinical pathology laboratory. The use of rapid on-site evaluation was also covered. Results.—: Sixteen guideline statements were developed to assist clinicians and pathologists in collecting and processing thoracic small biopsy and cytology tissue samples. Conclusions.—: Based on the systematic review and expert panel consensus, thoracic small specimens can be handled and processed to perform downstream testing (eg, molecular markers, immunohistochemical biomarkers), core needle and fine-needle techniques can provide appropriate cytologic and histologic specimens for ancillary studies, and rapid on-site cytologic evaluation remains helpful in appropriate triage, handling, and processing of specimens.
- 1 August 2020
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 144 (8) , 933-958
Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology
Context.—: The need for appropriate specimen use for ancillary testing has become more commonplace in the practice of pathology. This, coupled with improvements in technology, often provides less invasive methods of testing, but presents new challenges to appropriate specimen collection and handling of these small specimens, including thoracic small biopsy and cytology samples. Objective.—: To develop a clinical practice guideline including recommendations on how to obtain, handle, and process thoracic small biopsy and cytology tissue specimens for diagnostic testing and ancillary studies. Methods.—: The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. Core needle biopsy, touch preparation, fine-needle aspiration, and effusion specimens with thoracic diseases including malignancy, granulomatous process/sarcoidosis, and infection (eg, tuberculosis) were deemed within scope. Ancillary studies included immunohistochemistry and immunocytochemistry, fluorescence in situ hybridization, mutational analysis, flow cytometry, cytogenetics, and microbiologic studies routinely performed in the clinical pathology laboratory. The use of rapid on-site evaluation was also covered. Results.—: Sixteen guideline statements were developed to assist clinicians and pathologists in collecting and processing thoracic small biopsy and cytology tissue samples. Conclusions.—: Based on the systematic review and expert panel consensus, thoracic small specimens can be handled and processed to perform downstream testing (eg, molecular markers, immunohistochemical biomarkers), core needle and fine-needle techniques can provide appropriate cytologic and histologic specimens for ancillary studies, and rapid on-site cytologic evaluation remains helpful in appropriate triage, handling, and processing of specimens.
- Top Cited Papers
- 1 June 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (16) , 1631-1641
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Purpose: Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods: An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including pre-analytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results: The literature search identified 1,338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusion: The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity and clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, re-evaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.
- 1 June 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (16) , 1631-1641
Top Cited PapersCirculating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Purpose: Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods: An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including pre-analytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results: The literature search identified 1,338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusion: The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity and clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, re-evaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.
- 5 March 2018
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 142 (10) , 1242-1253
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Purpose.—: Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods.—: An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including preanalytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results.—: The literature search identified 1338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusions.—: The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens, and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity or clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, reevaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.
- 5 March 2018
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 142 (10) , 1242-1253
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Purpose.—: Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods.—: An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including preanalytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results.—: The literature search identified 1338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusions.—: The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens, and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity or clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, reevaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.
- Open Access
- 1 April 2016
- Published by University Library System, University of Pittsburgh in Journal of the Medical Library Association
- Vol. 104 (2) , 166-173
Research engagement of health sciences librarians: a survey of research-related activities and attitudes
The extent to which health sciences librarians are engaged in research is a little-studied question. This study assesses the research activities and attitudes of Medical Library Association (MLA) members, including the influence of work affiliation.An ...
- 1 April 2016
- Published by University Library System, University of Pittsburgh in Journal of the Medical Library Association
- Vol. 104 (2) , 166-173
Open AccessResearch engagement of health sciences librarians: a survey of research-related activities and attitudes
The extent to which health sciences librarians are engaged in research is a little-studied question. This study assesses the research activities and attitudes of Medical Library Association (MLA) members, including the influence of work affiliation.An ...
- Open Access
- 20 November 2015
- Published by IU Indianapolis University Library in Hypothesis
- Vol. 27 (1)
Report On The Hypothesis And Research Section Communication Survey
- 20 November 2015
- Published by IU Indianapolis University Library in Hypothesis
- Vol. 27 (1)
Open AccessReport On The Hypothesis And Research Section Communication Survey
- 23 October 2012
- Published by Taylor & Francis in Medical Reference Services Quarterly
- Vol. 31 (4) , 400-413
The Frontera Collaboration: A Preliminary Report of Health Sciences Librarians Promoting Evidence-Based Practice in U.S.-Mexico Border Communities
This article reviews the formation of the Frontera Collaboration, a coalition of health sciences librarians serving clinicians and public health personnel in the U.S.-Mexico border region. Based on findings from an assessment of the target populations’ learning needs, the Frontera Collaboration participants developed a shared set of training materials that have been used in pilot training sessions. The Frontera Collaboration's participants learned several lessons related to collaborative health information outreach and increased their understanding of the concerns and needs of clinicians and public health personnel serving border communities.
- 23 October 2012
- Published by Taylor & Francis in Medical Reference Services Quarterly
- Vol. 31 (4) , 400-413
The Frontera Collaboration: A Preliminary Report of Health Sciences Librarians Promoting Evidence-Based Practice in U.S.-Mexico Border Communities
This article reviews the formation of the Frontera Collaboration, a coalition of health sciences librarians serving clinicians and public health personnel in the U.S.-Mexico border region. Based on findings from an assessment of the target populations’ learning needs, the Frontera Collaboration participants developed a shared set of training materials that have been used in pilot training sessions. The Frontera Collaboration's participants learned several lessons related to collaborative health information outreach and increased their understanding of the concerns and needs of clinicians and public health personnel serving border communities.